The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Day One Biopharmaceuticals (I)
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Alexion Pharmaceuticals; Aptose Biosciences; Lynx Health
Honoraria - Array BioPharma; Cardinal Health; Curio Science
Consulting or Advisory Role - AADi; Advanced Accelerator Applications; Amgen; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Eisai; EMD Serono; Exelixis; Hutchison MediPharma; Incyte; Ipsen; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; Novartis; Pfizer; QED Therapeutics; Seagen; SERVIER; Stromatis Pharma; Takeda
Speakers' Bureau - IDEO Oncology
Research Funding - AstraZeneca (Inst); Bayer (Inst); BioNTech SE (Inst); Bristol Myers Squibb Foundation (Inst); Buzzard Pharmaceuticals; Camurus (Inst); Deciphera (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Innovative Cellular Therapeutics Co (Inst); Inspirna (Inst); Ipsen (Inst); ITM Oncologics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Nucana (Inst); REGENXBIO (Inst); Relay Therapeutics (Inst); Seattle Genetics/Astellas (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tempus (Inst); TransThera Biosciences (Inst); Zentalis (Inst)
Travel, Accommodations, Expenses - AADi; Camurus; Mirati Therapeutics; Nucana; Pfizer
A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.
 
Olivia Aranha
Consulting or Advisory Role - Seagen
Research Funding - Ipsen (Inst); Merck (Inst); Pfizer (Inst)
 
Milind M. Javle
Honoraria - AstraZeneca/MedImmune; EMD Serono/Merck; Incyte; Merck; QED Therapeutics; TransThera Biosciences
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Minori Koshiji Rosales
Employment - Macrogenics; The Compass Therapeutics
Leadership - Sesen Bio
Stock and Other Ownership Interests - Sesen Bio; The Compass Therapeutics
 
Zishuo Ian Hu
No Relationships to Disclose
 
Amir A. Faridi
No Relationships to Disclose
 
Scott Paulson
No Relationships to Disclose
 
Donald A. Richards
Consulting or Advisory Role - Grail; Ipsen; Mirati Therapeutics; Seattle Genetics/Astellas; Taiho Pharmaceutical
 
Howard S. Hochster
Stock and Other Ownership Interests - Compass Therapeutics; Processa Pharmaceuticals
Consulting or Advisory Role - Merck; Processa Pharmaceuticals
Other Relationship - seage
 
David Cosgrove
Employment - Compass Oncology
Leadership - Compass Oncology; Sarah Cannon Research Institute
Honoraria - EMD Serono
Consulting or Advisory Role - Daiichi Sankyo/Lilly; Genentech; Merck KGaA
Travel, Accommodations, Expenses - US Oncology
 
Nilofer Saba Azad
Stock and Other Ownership Interests - Haystack Oncology
Consulting or Advisory Role - AstraZeneca; Helsinn Therapeutics/QED Therapeutics; Incyte; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Merck; Mirati Therapeutics; QED Therapeutics; Taiho Pharmaceutical; Tempus
Speakers' Bureau - AstraZeneca
Research Funding - Agios (Inst); Array BioPharma (Inst); Astex Pharmaceuticals (Inst); AtlasMedx (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Intensity Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Ursa Brown-Glaberman
No Relationships to Disclose
 
Vivian Jean M. Cline
No Relationships to Disclose
 
Nathan M. Shumway
No Relationships to Disclose
 
Mohamedtaki Abdulaziz Tejani
Consulting or Advisory Role - Exelixis
Speakers' Bureau - Natera
Research Funding - Bayer (Inst)
 
Sujatha Nallapareddy
No Relationships to Disclose
 
Ilyas Sahin
No Relationships to Disclose
 
Mitesh J. Borad
Consulting or Advisory Role - BJ Bioscience; Genentech; Imvax; Kriya Therapeutics; Lynx Group; Merck; Senti Biosciences; Tempus; Zymeworks
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Basilea (Inst); Biond Biologics (Inst); Celgene (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Merck Serono (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Qurient (Inst); RedHill Biopharma (Inst); Relay Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Taiho Pharmaceutical (Inst); ZielBio (Inst)
 
Lipika Goyal
Consulting or Advisory Role - Alentis Therapeutics; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines; Compass Therapeutics; Eisai/H3 Biomedicine; Exelixis; Genentech; Incyte; Kinnate Biopharma; Merck; QED Therapeutics; SERVIER; Sirtex Medical; Synthekine; Taiho Pharmaceutical; TransThera Biosciences; Tyra Biosciences
(OPTIONAL) Uncompensated Relationships - Agios; Boehringer Ingelheim; Boehringer Ingelheim; Debiopharm Group; Merck; Taiho Pharmaceutical
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Compass Therapeutics; Elevar Therapeutics; Exelixis/Ipsen (Inst); Kinnate Biopharma; Merck (Inst); Regeneron; Tyra Biosciences
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Compass Therapeutics (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo/Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); SERVIER (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck